Gelesis Holdings Price to Free Cash Flow Ratio 2021-2022 | GLS
Historical price to free cash flow ratio values for Gelesis Holdings (GLS) since 2021.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Gelesis Holdings Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-02-03 |
0.33 |
|
0.05 |
| 2022-09-30 |
1.08 |
$6.95 |
0.16 |
| 2022-06-30 |
1.55 |
$7.44 |
0.21 |
| 2022-03-31 |
4.53 |
$1.96 |
2.31 |
| 2021-12-31 |
9.96 |
$-0.06 |
0.00 |
| 2021-09-30 |
9.92 |
$-7.94 |
0.00 |
| 2021-06-30 |
9.79 |
$-8.13 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.024B |
$0.011B |
|
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
|
